Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase

Journal of Controlled Release

Volumn 159, Issue 1, 2012, Pages 92-103

  Noga, Matthäus ^a   Edinger, Daniel ^a   Rödl, Wolfgang ^a   Wagner, Ernst ^a   Winter, Gerhard ^a   Besheer, Ahmed ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bioreversible coats; Hydroxyethyl starch (HES); Nucleic acid delivery; Polyplexes; Shielding and deshielding

Indexed keywords

BIOREVERSIBLE COATS; BLOOD STREAMS; CELL LINES; CULTURE MEDIUM; DESHIELDING; ERYTHROCYTE AGGREGATION; EXTRACELLULAR; GENE DELIVERY; HYDROXYETHYL STARCH (HES); IN-VITRO; NONVIRAL; ORDERS OF MAGNITUDE; PEGYLATION; PLASMID DNA; POLYETHYLENIMINES; POLYPLEXES; POSITIVE CHARGES; THERAPEUTIC MODALITY; TRANSFECTION EFFICIENCY; ZETA POTENTIAL MEASUREMENTS;

AMYLASES; ANTIGEN-ANTIBODY REACTIONS; CELL CULTURE; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE TRANSFER; NANOPARTICLES; NUCLEIC ACIDS; STARCH; ZETA POTENTIAL;

SHIELDING;

AMYLASE; HYDROXYETHYLCELLULOSE; LUCIFERASE; MACROGOL; NANOPARTICLE; PLASMID DNA; POLYETHYLENEIMINE;

ANIMAL CELL; ARTICLE; BIODEGRADATION; CHEMICAL MODIFICATION; COLORIMETRY; CONJUGATE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ERYTHROCYTE AGGREGATION; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; HYDROLYSIS; IN VITRO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; ZETA POTENTIAL;

ALPHA-AMYLASES; ANIMALS; CELL LINE, TUMOR; DNA; GENE TRANSFER TECHNIQUES; HETASTARCH; HUMANS; LUCIFERASES; MICE; PLASMIDS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE;

EID: 84859505630     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.006     Document Type: Article

References (53)

1. T. Friedmann, and R. Roblin Gene therapy for human genetic disease? Science 175 1972 949 955
2. A.K. Iyer, G. Khaled, J. Fang, and H. Maeda Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 2006 812 818
3. H. Maeda, T. Sawa, and T. Konno Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control. Release 74 2001 47 61
4. T. Merdan, K. Kunath, H. Petersen, U. Bakowsky, K.H. Voigt, J. Kopecek, and T. Kissel PEGylation of Poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice Bioconjug. Chem. 16 2005 785 792
5. M. Kursa, G.F. Walker, V. Roessler, M. Ogris, W. Roedl, R. Kircheis, and E. Wagner Novel shielded transferrin-polyethylene glycol-polyethylenimine/dna complexes for systemic tumor-targeted gene transfer Bioconjug. Chem. 14 2003 222 231
6. C. Nicolazzi, N. Mignet, N. de la Figuera, M. Cadet, R.T. Ibad, J. Seguin, D. Scherman, and M. Bessodes Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time J. Control. Release 88 2003 429 443
7. A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, G. Fisch, S. Dames, K. Loffler, M. Fechtner, W. Arnold, K. Giese, A. Klippel, and J. Kaufmann A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther. 13 2006 1222 1234
8. J.M. Harris, and R.B. Chess Effect of PEGylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
9. L. Xu, and T. Anchordoquy Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics J. Pharm. Sci. 100 2011 38 52
10. R.H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19
11. Y.S. Park, and L. Huang Effect of chemically modified G(M1) and neoglycolipid analogs of G(M1) on liposome circulation time - evidence supporting the dysopsonin hypothesis Biochim. Biophys. Acta 1166 1993 105 114
12. I. Lynch, and K.A. Dawson Protein-nanoparticle interactions Nano Today 3 2008 40 47
13. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152
14. S. Mishra, P. Webster, and M.E. Davis PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles Eur. J. Cell Biol. 83 2004 97 111
15. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 3 2011 152 160
16. G. dlakha-Hutcheon, M.B. Bally, C.R. Shew, and T.D. Madden Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity Nat. Biotechnol. 17 1999 775 779
17. V. Knorr, M. Ogris, and E. Wagner An acid sensitive ketal-based polyethylene glycol-oligoethylenimine copolymer mediates improved transfection efficiency at reduced toxicity Pharm. Res. 25 2008 2937 2945
18. V. Knorr, V. Russ, L. Allmendinger, M. Ogris, and E. Wagner Acetal linked oligoethylenimines for use as pH-sensitive gene carriers Bioconjug. Chem. 19 2008 1625 1634
19. Y. Nie, M. Gunther, Z.W. Gu, and E. Wagner Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding Biomaterials 32 2011 858 869
20. G.F. Walker, C. Fella, J. Pelisek, J. Fahrmeir, S. Boeckle, M. Ogris, and E. Wagner Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo Mol. Ther. 11 2005 418 425
21. S. Takae, K. Miyata, M. Oba, T. Ishii, N. Nishiyama, K. Itaka, Y. Yamasaki, H. Koyama, and K. Kataoka PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors J. Am. Chem. Soc. 130 2008 6001 6009
22. H. Hatakeyama, H. Akita, K. Kogure, M. Oishi, Y. Nagasaki, Y. Kihira, M. Ueno, H. Kobayashi, H. Kikuchi, and H. Harashima Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid Gene Ther. 14 2006 68 77
23. J.X. Zhang, S. Zalipsky, N. Mullah, M. Pechar, and T.M. Allen Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers Pharmacol. Res. 49 2004 185 198
24. B. Romberg, W.E. Hennink, and G. Storm Sheddable coatings for long-circulating nanoparticles Pharm. Res. 25 2008 55 71
25. Y. Lee, H. Koo, G.W. Jin, H.J. Mo, M.Y. Cho, J.Y. Park, J.S. Choi, and J.S. Park Poly(ethylene oxide sulfide): new poly(ethylene glycol) derivatives degradable in reductive conditions Biomacromolecules 6 2005 24 26
26. B. Romberg, F.M. Flesch, W.E. Hennink, and G. Storm Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes Int. J. Pharm. 355 2008 108 113
27. B. Romberg, C. Oussoren, C.J. Snel, M.G. Carstens, W.E. Hennink, and G. Storm Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration Biochim. Biophys. Acta-Biomembr. 1768 2007 737 743
28. R. Duncan, H.R.P. Gilbert, R.J. Carbajo, and M.J. Vicent Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conjugates designed for alpha-amylase activation Biomacromolecules 9 2008 1146 1154
29. E.L. Ferguson, and R. Duncan Dextrin-phospholipase A(2): synthesis and evaluation as a bioresponsive anticancer conjugate Biomacromolecules 10 2009 1358 1364
30. J. Hardwicke, E.L. Ferguson, R. Moseley, P. Stephens, D.W. Thomas, and R. Duncan Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair J. Control. Release 130 2008 275 283
31. G. Audibert, M. Dormer, J.C. Lefèvre, J.F. Stoltz, and M.C. Laxenaire Rheologic effects of plasma substitutes used for preoperative hemodilution Anesth. Analg. 78 1994 740 745
32. Y. Sakr, D. Payen, K. Reinhart, F.S. Sipmann, E. Zavala, J. Bewley, G. Marx, and J.-L. Vincent Effects of hydroxyethyl starch administration on renal function in critically ill patients Br. J. Anaesth. 98 2007 216 224
33. B.B. Warren, and M.E. Durieux Hydroxyethyl starch: safe or not? Anesth. Analg. 84 1997 206 212
34. M. Yoshida, and T. Kishikawa A study of hydroxyethyl starch. part ii. degradation-sites of hydroxyethyl starch by pig pancreas alpha-amylase Starch-Starke 36 1984 167 169
35. M. Yoshida, T. Yamashita, J. Matsuo, and T. Kishikawa Enzymic degradation of hydroxyethyl starch. Part I. Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch Starch-Starke 25 1973 373 376
36. J. Treib, J.F. Baron, M.T. Grauer, and R.G. Strauss An international view of hydroxyethyl starches Intensive Care Med. 25 1999 258 268
37. A. Besheer, G. Hause, J. Kressler, and K. Mäder Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles Biomacromolecules 8 2007 359 367
38. A. Besheer, H. Caysa, H. Metz, T. Mueller, J. Kressler, and K. Mäder Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES) Int. J. Pharm. 417 1-2 2011 196 203
39. A. Besheer, T.C. Hertel, J. Kressler, K. Mäder, and M. Pietzsch Enzymatically catalyzed HES conjugation using microbial transglutaminase: proof of feasibility J. Pharm. Sci. 98 2009 4420 4428
40. M. Orlando Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES) 2003 Justus Liebig UniversitÇÏt Giessen
41. D. Oupicky, M. Ogris, K.A. Howard, P.R. Dash, K. Ulbrich, and L.W. Seymour Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation Mol. Ther. 5 2002 463 472
42. D. Schaffert, M. Kiss, W. Rödl, A. Shir, A. Levitzki, M. Ogris, and E. Wagner Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier Pharm. Res. 28 2011 731 741
43. C. Plank, K. Zatloukal, M. Cotten, K. Mechtler, and E. Wagner Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand Bioconjug. Chem. 3 1992 533 539
44. E. Nitsch Process for the production of starch degradation products with a narrow molecular weight distribution Application: US US 1995 Laevosan-Gesellschaft mbH Austria
45. A. Besheer Nanomedicines based on modified hydroxyethyl starch: From synthesis to in vivo evaluation Naturwissenschaftliche Fakultät I, Biowissenschaften 2009 Martin-Luther-Universität, Halle-Wittenberg Halle-Wittenberg
46. R. Kircheis, L. Wightman, A. Schreiber, B. Robitza, V. Rossler, M. Kursa, and E. Wagner Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application Gene Ther. 8 2001 28 40
47. F. Ungaro, G. De Rosa, A. Miro, and F. Quaglia Spectrophotometric determination of polyethylenimine in the presence of an oligonucleotide for the characterization of controlled release formulations J. Pharm. Biomed. Anal. 31 2003 143 149
48. M.L. Caldwell, and J-F.T. Kung A study of the influence of a number of factors upon the stability and upon the activity of pancreatic amylase1 J. Am. Chem. Soc. 75 13 1953 3132 3135
49. A. Wollrab, Organische Chemie, in: Springer-Verlag (Ed.), Berlin Heidelberg, 2009, pp. 495, 496.
50. J.P. Bretaudiere, R. Rej, P. Drake, A. Vassault, and M. Bailly Suitability of control materials for determination of alpha-amylase activity Clin. Chem. 27 1981 806 815
51. S.D. Li, and L. Huang Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting J. Control. Release 145 2010 178 181
52. R. Hoogenboom, M.W.M. Fijten, C. Brandli, J. Schroer, and U.S. Schubert Automated parallel temperature optimization and determination of activation energy for the living cationic polymerization of 2-ethyl-2-oxazoline Macromol. Rapid Commun. 24 1 2003 98 103
53. A. Besheer, J. Vogel, D. Glanz, J. Kressler, T. Groth, and K. Mäder Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs pluronics Mol. Pharm. 6 2009 407 415